<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide is an anti-angiogenic agent currently used to treat patients with malignant <z:hpo ids='HP_0004326'>cachexia</z:hpo> or <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Lenalidomide (CC-5013) is an immunomodulatory thalidomide analogue licensed in the United States of America (USA) for the treatment of a subtype of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This two-centre, open-label phase I study evaluated dose-limiting toxicities in 55 patients with <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumours</z:e> refractory to standard chemotherapies </plain></SENT>
<SENT sid="3" pm="."><plain>Lenalidomide capsules were consumed once daily for 12 weeks according to one of the following three schedules: (I) 25 mg daily for the first 7 d, the daily dose increased by 25 mg each week up to a maximum daily dose of 150 mg; (II) 25mg daily for 21 d followed by a 7-d rest period, the 4-week cycle repeated for 3 cycles; (III) 10 mg daily continuously </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-six patients completed the study period </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients experienced a grade 3 hypersensitivity <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients in cohort I and 4 patients in cohort II suffered grade 3 or 4 neutropaenia </plain></SENT>
<SENT sid="7" pm="."><plain>In 2 patients with predisposing medical factors, grade 3 cardiac dysrhythmia was recorded </plain></SENT>
<SENT sid="8" pm="."><plain>Grade 1 neurotoxicity was detected in 6 patients </plain></SENT>
<SENT sid="9" pm="."><plain>One complete and two partial radiological responses were measured by computed tomography scanning; 8 patients had stable disease after 12 weeks of treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Fifteen patients remained on treatment as named patients; 1 with metastatic <z:hpo ids='HP_0002861'>melanoma</z:hpo> remains in clinical remission 3.5 years from trial entry </plain></SENT>
<SENT sid="11" pm="."><plain>This study indicates the tolerability and potential clinical efficacy of lenalidomide in patients with advanced <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> who have previously received multi-modality treatment </plain></SENT>
<SENT sid="12" pm="."><plain>Depending on the extent of myelosuppressive pre-treatment, dose schedules (II) or (III) are advocated for large-scale trials of long-term administration </plain></SENT>
</text></document>